Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature

References

• CRUKThyroid cancer incidence statistics2015 Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/incidenceAccessed January 05, 2017
   Google Scholar
• DaviesLWelchHGIncreasing incidence of thyroid cancer in the United States, 1973–2002JAMA2006295182164216716684987
   PubMed Web of Science ®Google Scholar
• McLeodDSSawkaAMCooperDSControversies in primary treatment of low-risk papillary thyroid cancerLancet201338198711046105723668555
   PubMed Web of Science ®Google Scholar
• BassettJHO’SheaPJSriskantharajahSThyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidismMol Endocrinol20072151095110717327419
   PubMedGoogle Scholar
• MonfouletLERabierBDacquinRThyroid hormone receptor β mediates thyroid hormone effects on bone remodeling and bone massJ Bone Miner Res20112692036204421594896
   PubMed Web of Science ®Google Scholar
• AbeEMariansRCYuWTSH is a negative regulator of skeletal remodelingCell2003115215116214567913
   PubMed Web of Science ®Google Scholar
• KleinIOjamaaKThyroid hormone and the cardiovascular systemN Engl J Med2001344750150911172193
   PubMed Web of Science ®Google Scholar
• ErtekSCiceroAFHyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiologyArch Med Sci20139594495224273583
   PubMed Web of Science ®Google Scholar
• RubinMRBilezikianJPHypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacementArq Bras Endocrinol Metabol201054222022620485912
   PubMedGoogle Scholar
• GoswamiRSharmaRSreenivasVGuptaNGanapathyADasSPrevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidismClin Endocrinol2012772200206
   Web of Science ®Google Scholar
• SpenceLAWeaverCMCalcium intake, vascular calcification, and vascular diseaseNutr Rev2013711152223282248
   PubMed Web of Science ®Google Scholar
• EdafeOAntakiaRLaskarNUttleyLBalasubramanianSPSystematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemiaBr J Surg2014101430732024402815
   PubMed Web of Science ®Google Scholar
• UnderbjergLSikjaerTMosekildeLRejnmarkLPostsurgical hypoparathyroidism–risk of fractures, psychiatric diseases, cancer, cataract, and infectionsJ Bone Miner Res201429112504251024806578
   PubMed Web of Science ®Google Scholar
• QuanMLPasiekaJLRorstadOBone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literatureJ Surg Oncol2002791627011754378
   PubMed Web of Science ®Google Scholar
• HeemstraKAHamdyNARomijnJASmitJWThe effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinomaThyroid200616658359116839260
   PubMed Web of Science ®Google Scholar
• MoonJHAhnSSeoJThe effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinomaJ Clin Endocrinol Metab201499103782378925029415
   PubMed Web of Science ®Google Scholar
• TournisSAntoniouJDLiakouCGVolumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppressionClin Endocrinol (Oxf)201582219720425040693
   PubMed Web of Science ®Google Scholar
• HawkinsFRigopoulouDPapapietroKLopezMBSpinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditisCalcif Tissue Int199454116198118747
   PubMed Web of Science ®Google Scholar
• FruscianteVCarnevaleVScillitaniAGlobal skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancerEur J Nucl Med19982521391439473261
   PubMedGoogle Scholar
• MikoschPJaukBGallowitschHJPipamWKresnikELindPSuppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolismThyroid200111325726311327617
   PubMed Web of Science ®Google Scholar
• ChenCHChenJFYangBYBone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinomaJ Formos Med Assoc20041066442447
   Google Scholar
• ReverterJLHolgadoSAlonsoNSalinasIGranadaMLSanmartiALack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinomaEndocr Relat Cancer200512497398116322336
   PubMed Web of Science ®Google Scholar
• SajjinanontTRajchadaraSSriassawaamornNPanichkulSThe comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal womenJ Med Assoc Thai200588Suppl 3S71S7616858944
   PubMedGoogle Scholar
• Botella-CarreteroJIAlvarez-BlascoFSan MillanJLEscobar-MorrealeHFThyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in womenEur J Endocrinol2007156553954517468189
   PubMed Web of Science ®Google Scholar
• SugitaniIFujimotoYEffect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled studySurgery201115061250125722136848
   PubMed Web of Science ®Google Scholar
• FlorkowskiCMBrownlieBEElliotJRAylingEMTurnerJGBone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinomaN Z Med J19931069664434448233173
   PubMed Web of Science ®Google Scholar
• FujiyamaKKiriyamaTItoMSuppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal womenThyroid19955113177787427
   PubMed Web of Science ®Google Scholar
• GiustiMCecoliFFazzuoliLSerum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort studyMetabolism200756569970717445547
   PubMed Web of Science ®Google Scholar
• PanicoALupoliGAFondericoFOsteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronateThyroid200919543744219415993
   PubMed Web of Science ®Google Scholar
• McDermottMTPerloffJJKiddGSA longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancerCalcif Tissue Int19955665215257648478
   PubMed Web of Science ®Google Scholar
• FujiyamaKKiriyamaTItoMAttenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidismJ Clin Endocrinol Metab1995807213521387608266
   PubMed Web of Science ®Google Scholar
• ReverterJLColomeEHolgadoSBone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinomaEndocrine201037346747220960170
   PubMed Web of Science ®Google Scholar
• GianniniSNobileMSartoriLBone density and mineral metabolism in thyroidectomized patients treated with long-term L-thyroxineClin Sci (Lond)19948755935977874849
   PubMed Web of Science ®Google Scholar
• JodarEBegona LopezMGarciaLRigopoulouDMartinezGHawkinsFBone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone massOsteoporos Int19988431131610024900
   PubMed Web of Science ®Google Scholar
• KungAWLorentzTTamSCThyroxine suppressive therapy decreases bone mineral density in post-menopausal womenClin Endocrinol1993395535540
   Web of Science ®Google Scholar
• MullerCGBayleyTAHarrisonJETsangRPossible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevanceThyroid19955281877647577
   PubMed Web of Science ®Google Scholar
• MazziottiGSorvilloFPiscopoMRecombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinomaJ Bone Miner Res200520348048615746993
   PubMed Web of Science ®Google Scholar
• DiamondTNeryLHalesIA therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinomaJ Clin Endocrinol Metab1991726118411882026740
   PubMed Web of Science ®Google Scholar
• EftekhariMAsadollahiABeikiDThe long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatmentHell J Nucl Med200811316016319081859
   PubMed Web of Science ®Google Scholar
• FranklynJABetteridgeJDaykinJLong-term thyroxine treatment and bone mineral densityLancet199234088109131351654
   PubMed Web of Science ®Google Scholar
• GorresGKaimAOtteAGotzeMMuller-BrandJBone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinomaEur J Nucl Med19962366906928662104
   PubMedGoogle Scholar
• GuoCYWeetmanAPEastellRLongitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxineClin Endocrinol (Oxf)19974633013079156039
   PubMed Web of Science ®Google Scholar
• HeijckmannACHuijbertsMSGeusensPde VriesJMenheerePPWolffenbuttelBHHip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinomaEur J Endocrinol20051531232915994742
   PubMed Web of Science ®Google Scholar
• MartiniGGennariLDe PaolaVThe effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levelsThyroid200818445546018399769
   PubMed Web of Science ®Google Scholar
• SchneiderRSchneiderMReinersCSchneiderPEffects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort studyJ Clin Endocrinol Metab201297113926393422977269
   PubMed Web of Science ®Google Scholar
• ToivonenJTahtelaRLaitinenKRisteliJValimakiMJMarkers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapyEur J Endocrinol199813866676739678534
   PubMed Web of Science ®Google Scholar
• Klein HesselinkENKlein HesselinkMSde BockGHLong-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational studyJ Clin Oncol201331324046405324101052
   PubMed Web of Science ®Google Scholar
• ShapiroLESievertROngLMinimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxineJ Clin Endocrinol Metab1997828259225959253339
   PubMed Web of Science ®Google Scholar
• Vigario PdosSChachamovitzDSTeixeira PdeFSantosMAOliveiraFPVaismanMImpaired functional and hemodynamic response to graded exercise testing and its recovery in patients with subclinical hyperthyroidismArq Bras Endocrinol Metabol201155320321221655869
   PubMedGoogle Scholar
• Botella-CarreteroJIGomez-BuenoMBarriosVChronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinomaEndocr Relat Cancer200411234535615163309
   PubMed Web of Science ®Google Scholar
• MurialdoGCasuMCappiCEffects of recombinant human thyrotropin on heart rate variability and blood pressure in patients on l-thyroxine-suppressive therapy for differentiated thyroid carcinomaHorm Res2005642100106
   Google Scholar
• ShuvyMArbelleJEGrosbardAKatzAA simple test of one minute heart rate variability during deep breathing for evaluation of sympatovagal imbalance in hyperthyroidismIsr Med Assoc J2008108–960360618847162
   PubMed Web of Science ®Google Scholar
• TaillardVSardinouxMOudotCEarly detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapyClin Endocrinol (Oxf)201175570971421645022
   PubMed Web of Science ®Google Scholar
• AbdulrahmanRMDelgadoVHoftijzerHCBoth exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinomaThyroid201121547147621417919
   PubMed Web of Science ®Google Scholar
• HoftijzerHCBaxJJHeemstraKAShort-term overt hypothyroidism induces discrete diastolic dysfunction in patients treated for differentiated thyroid carcinomaEur J Clin Invest200939320421019260950
   PubMed Web of Science ®Google Scholar
• ShargorodskyMSerovSGavishDLeibovitzEHarpazDZimlichmanRLong-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinomaThyroid200616438138616646685
   PubMed Web of Science ®Google Scholar
• CasuMCappiCPatroneVSympatho-vagal control of heart rate variability in patients treated with suppressive doses of L-thyroxine for thyroid cancerEur J Endocrinol2005152681982415941920
   PubMed Web of Science ®Google Scholar
• MittalAPoudelBPandeyaDRGuptaSPSathianBYadavSKMetabolic changes enhance the cardiovascular risk with differentiated thyroid carcinoma–a case control study from Manipal Teaching Hospital of NepalAsian Pac J Cancer Prev20121352335233822901217
   PubMedGoogle Scholar
• DardanoAGhiadoniLPlantingaYRecombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinomaJ Clin Endocrinol Metab200691104175417816868055
   PubMed Web of Science ®Google Scholar
• AbonowaraAQuraishiASappJLPrevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancerClin Invest Med2012353E152E15622673318
   PubMed Web of Science ®Google Scholar
• GenRAkbayECamsariAOzcanTP-wave dispersion in endogenous and exogenous subclinical hyperthyroidismJ Endocrinol Invest2010332889119636214
   PubMed Web of Science ®Google Scholar
• JaraczJKucharskaARajewska-RagerALackaKCognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinomaJ Endocrinol Invest201235876076521986400
   PubMed Web of Science ®Google Scholar
• Botella-CarreteroJIGalanJMCaballeroCSanchoJEscobar-MorrealeHFQuality of life and psychometric functionality in patients with differentiated thyroid carcinomaEndocr Relat Cancer200310460161014713270
   PubMed Web of Science ®Google Scholar
• CrevennaRZettinigGKeilaniMQuality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapySuppor Care Cancer2003119597603
   Web of Science ®Google Scholar
• Eustatia-RuttenCFCorssmitEPPereiraAMQuality of life in long-term exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trialClin Endocrinol2006643284291
   Web of Science ®Google Scholar
• HoftijzerHCHeemstraKACorssmitEPvan der KlaauwAARomijnJASmitJWQuality of life in cured patients with differentiated thyroid carcinomaJ Clin Endocrinol Metab200893120020317956954
   PubMed Web of Science ®Google Scholar
• TagaySHerpertzSLangkafelMHealth-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatmentEur J Endocrinol2005153675576316322380
   PubMed Web of Science ®Google Scholar
• Vigario PdosSChachamovitzDSCordeiroMFEffects of physical activity on body composition and fatigue perception in patients on thyrotropin-suppressive therapy for differentiated thyroid carcinomaThyroid201121769570021615309
   PubMed Web of Science ®Google Scholar
• Vigario PdosSChachamovitzDSTeixeira PdeFRocque MdeLSantosMLVaismanMExercise is associated with better quality of life in patients on TSH-suppressive therapy with levothyroxine for differentiated thyroid carcinomaArq Bras Endocrinol Metabol201458327428124863090
   PubMedGoogle Scholar
• HeemstraKASmitJWEustatia-RuttenCFGlucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trialClin Endocrinol2006656737744
   Web of Science ®Google Scholar
• HsiehCJWangPWWangSTSerum leptin concentrations of patients with sequential thyroid function changesClin Endocrinol20025712934
   Web of Science ®Google Scholar
• RezzonicoJNiepomniszczeHRezzonicoMPusiolEAlbertoMBrentaGThe association of insulin resistance with subclinical thyrotoxicosisThyroid201121994594921834678
   PubMed Web of Science ®Google Scholar
• HorneMKSinghKKRosenfeldKGIs thyroid hormone suppression therapy prothrombotic?J Clin Endocrinol Metab20048994469447315356049
   PubMed Web of Science ®Google Scholar
• Botella-CarreteroJIPradosAManzanoLThe effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawalEur J Endocrinol2005153222323016061828
   PubMed Web of Science ®Google Scholar
• SmitJWEustatia-RuttenCFCorssmitEPReversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled studyJ Clin Endocrinol Metab200590116041604716131580
   PubMed Web of Science ®Google Scholar
• BiondiBFazioSCarellaCControl of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxineJ Clin Endocrinol Metab1994785102810338175955
   PubMed Web of Science ®Google Scholar
• GulluSAltuntasFDincerIErolCKamelNEffects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunctionEur J Endocrinol2004150565566115132721
   PubMed Web of Science ®Google Scholar
• ChanFKTiuSCChoiKLChoiCHKongAPShekCCIncreased bone mineral density in patients with chronic hypoparathyroidismJ Clin Endocrinol Metab20038873155315912843159
   PubMed Web of Science ®Google Scholar
• MucsiIHerczGRelative hypoparathyroidism and adynamic bone diseaseAm J Med Sci1999317640540910372841
   PubMed Web of Science ®Google Scholar
• MikoschPObermayer-PietschBJostRBone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatmentThyroid200313434735612804103
   PubMed Web of Science ®Google Scholar
• TaimelaETaimelaSNikkanenVIrjalaKAccelerated bone degradation in thyroid carcinoma patients during thyroxine treatment, measured by determination of the carboxyterminal telopeptide region of type I collagen in serumEur J Clin Chem Clin Biochem199432118278317888478
   PubMedGoogle Scholar
• MikoschPIgercIKudlacekSReceptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancerEur J Clin Invest200636856657316893379
   PubMed Web of Science ®Google Scholar
• MikoschPKerschan-SchindlKWoloszczukWHigh cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapyThyroid2008181273318302515
   PubMed Web of Science ®Google Scholar